Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

AMGN - Amgen Inc. Latest News | Finranks

Home

AMGN

A

Amgen Inc. (AMGN)

NMS – Real Time Price. Currency in USD

348.77

-4.39 (-1.24%)

At close: Mar 27, 2026, 4:00 PM EDT

349.38

+0.61 (0.17%)

After-hours: Mar 27, 2026, 7:53 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha in High-Risk Patients, with Median 44 mg/dL LDL-C Achieved THOUSAND OAKS, Calif., March 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that Repatha® (evolocumab), when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments, reduced the risk of first major adverse cardiovascular (CV) events (MACE) in high-risk primary prevention patients without known significant atherosclerosis (buildup of plaque in the arteries) and with diabetes.

Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

In the most recent trading session, Amgen (AMGN) closed at $353.93, indicating a +1.58% shift from the previous trading day.

AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock?

AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock?

Amgen stock holds above key SMAs as strong drug sales, biosimilars, and MariTide pipeline momentum offset looming patent losses and pricing headwinds.

TrumpRx lists many medicines at prices higher than paid in UK

TrumpRx lists many medicines at prices higher than paid in UK

U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those paid in the United Kingdom, according to a Reuters comparison of publicly available prices.

Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

Amgen (AMGN) closed at $361.13 in the latest trading session, marking a -1.4% move from the prior day.

Is Trending Stock Amgen Inc. (AMGN) a Buy Now?

Is Trending Stock Amgen Inc. (AMGN) a Buy Now?

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Videos

Amgen CEO Bob Bradway goes one-on-one with Jim Cramer

Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss

Press releases

REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha in High-Risk Patients, with Median 44 mg/dL LDL-C Achieved THOUSAND OAKS, Calif., March 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that Repatha® (evolocumab), when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments, reduced the risk of first major adverse cardiovascular (CV) events (MACE) in high-risk primary prevention patients without known significant atherosclerosis (buildup of plaque in the arteries) and with diabetes.

19.12.2025

Neutral

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

Trade Tracker: Bill Baruch buys more Amgen

AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

THOUSAND OAKS, Calif., March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the second quarter of 2026.

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

THOUSAND OAKS, Calif., Feb. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the comparable periods in 2024.

Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access

Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access

LAS VEGAS--(BUSINESS WIRE)--Sagebrush Health Services, a nonprofit organization serving over 10,000 Nevada patients, has filed a lawsuit against Amgen Inc. (NASDAQ: AMGN), alleging that Amgen acted unlawfully by unilaterally terminating the sale of discounted drugs to Sagebrush's clinics and improperly retracting millions of dollars in past discounts. These actions, Sagebrush maintains, temporarily prevented it from supplying its clinics with necessary medications from Amgen and other manufactu.